Corrigendum to "Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections" [Advanced Drug Delivery Reviews 60 (2008)692-701] (DOI:10.1016/j.addr.2007.08.042);Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections

Advanced Drug Delivery Reviews

Volumn 60, Issue 6, 2008, Pages 692-701

  Sachs Barrable, Kristina ^a   Lee, Stephen D ^a   Wasan, Ellen K ^a,b   Thornton, Sheila J ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

Amphotericin B; Antifungal activity; Gastrointestinal absorption; Lymphatic drug transport; Oral formulation; P glycoprotein; Peceol ; Pharmacokinetics; Renal toxicity

Indexed keywords

ABSORPTION; FUNGI; LIPIDS; PHARMACOKINETICS; TOXICITY;

AMPHOTERICIN B; ANTIFUNGAL ACTIVITY; GASTROINTESTINAL ABSORPTION; LYMPHATIC DRUG TRANSPORT; ORAL FORMULATION; P-GLYCOPROTEIN; RENAL TOXICITY;

DRUG DELIVERY;

ACCONON; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CAPTEX; CREMOPHOR; DEOXYCHOLIC ACID; EXCIPIENT; GELUCIRE; INTRALIPID; LIPID; METHANOL; OCTANOIN; PECEOL; POLOXAMER; POLYSORBATE 80; SOLUTOL HS 15; SURFACTANT; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; EMULSION; GASTROINTESTINAL ABSORPTION; LYMPHATIC SYSTEM; MICELLE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

EID: 39149137830     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.09.003     Document Type: Erratum

References (51)

1. Thakur C.P., Pandey A.K., Sinha G.P., Roy S., Behbehani K., and Oilliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans. R. Soc. Trop. Med. Hyg. 90 (1996) 319-322
2. Gates C., and Pinney R.J. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 18 (1993) 147-153
3. Meyer R.D. Current role of therapy with amphotericin B. Clin. Infect. Dis. 14 (1992) S154-S160
4. Risovic V., Boyd M., Choo E., and Wasan K.M. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob. Agents Chemother. 47 (2003) 3339-3342
5. Risovic V., Sachs-Barrable K., Boyd M., and Wasan K.M. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev. Ind. Pharm. 30 (2004) 767-774
6. Risovic V., Rosland M., Sivak O., and Wasan K.M. Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus. Drug Development and Industrial Pharmacy 33 (2007) 703-707
7. Porter C.J., and Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50 (2001) 61-80
8. Trevaskis N.L., Porter C.J., and Charman W.N. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab. Dispos. 34 (2006) 729-733
9. Sieber S.M. The lymphocytic absorption of p,p′-DDT and some structurally-related compounds in the rat. Pharmacology 14 (1976) 443-454
10. Porter C.J.H., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of drugs. Nat. Rev. Drug Discov. 6 (2007) 231-248
11. Charman W.N., and Stella V.J. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34 (1986) 175-178
12. Wasan K.M., Kennedy A.L., Cassidy S.M., Ramaswamy M., Holtorf L., Chou J.W.L., and Pritchard P.H. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42 (1998) 3146-3152
13. Dangi J.S., Vyas S.P., and Dixit V.K. Effect of various lipid bile salt mixed micelles on intestinal absorption of amphotericin B in rat. Drug Dev. Ind. Pharm. 24 (1998) 631-635
14. Lance M.R., Washington C., and Davis S.S. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J. Antimicrob. Chemother. 36 (1995) 119-128
15. Souza L.C., Saldiva P.H., and Campa A. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study. Exp. Toxicol. Pathol. 52 (2000) 169-175
16. Brigui I., Djavantakht-Samani T., Jolles B., Pigaglio S., and Laigle A. Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1. Biochem. Pharmacol. 65 (2003) 747-754
17. Kolaczkowski M., Kolaczkowska A., Luczynski J., Witek S., and Goffeau A. In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network. Microb. Drug Resist.-Mechanisms Epidemiology and Disease 4 (1998) 143-158
18. White T.C. Antimicrob. Agents Chemother. 47 (2003) 1482-1487
19. Davidson N.O. Cellular and molecular mechanisms of small intestinal lipid transport. In: Johnson L.R. (Ed). Physiology of the GastroIntestinal Tract. 3rd ed (1994), Raven Press, New York 1909-1934
20. Johnson J.M. Triglyceride biosynthesis in the intestinal mucosa. In: Rommel K., Goebell H., and Bohmer R. (Eds). Lipid Absorption: Biochemical and Clinical Aspects (1976), MTP Press, Lancaster 85-94
21. Zilversmit D.B. The composition and structure of lymph chylomicrons in dog, rat, and man. J. Clin. Invest. 44 (1965) 1610-1622
22. McDonald G.B., and Weidman M. Partitioning of polar fatty acids into lymph and portal vein after intestinal absorption in the rat. Q.J. Exp. Physiol. 72 (1987) 153-159
23. Hofmann A.F., and Borgstrom B. Physico-chemical state of lipids in intestinal content during their digestion and absorption. Fed. Proc. 21 (1962) 43-50
24. White D.G., Story M.J., and Barnwell S.G. Int. J. Pharm. 69 (1991) 169-174
25. McDonald G.B., Saunders D.R., Weidman M., and Fisher L. Portal venous transport of long-chain fatty acids absorbed from rat intestine. Am. J. Physiol. 239 (1980) G141-G150
26. Bugaut M., and Carlier H. Role of intestinal hydrolases, endogenous substrates and chyloportal partition in fat absorption. In: Kuksis A. (Ed). Fat Absorption vol. 1 (1987), CRC Press, Boca Raton 197-232
27. Boyd M., Risovic V., Jull P., Choo E., and Wasan K.M. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat. J. Pharmacol. Toxicol. Methods 49 (2004) 115-120
28. Hauss D.J., Fogal S.E., Ficorilli J.V., Price C.A., Roy T., Jayaraj A.A., and Keirns J.J. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87 (1998) 165-169
29. Chan L.M., Lowes S., and Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21 (2004) 25-51
30. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., and Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
31. Juliano R.J., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys Acta 455 (1976) 152-162
32. Roninson I.B., Chin J.E., Choi K.G., Gros P., Housman D.E., Fojo A., Shen D.W., Gottesman M.M., and Pastan I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 4538-4542
33. Fardel O., Lecureur V., and Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27 (1996) 1283-1291
34. Roepe P.D. What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance?. Curr. Pharm. Des. 6 (2000) 241-260
35. Sugiyama Y., Kusuhara H., and Suzuki H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J. Control. Release 62 (1999) 179-186
36. Ouar Z., Lacave R., Bens M., and Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells. Cell Biol. Toxicol. 15 (1999) 91-100
37. Orlowski S., and Garrigos M. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res. 19 (1999) 3109-3123
38. Nielsen D., and Skovsgaard T. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim. Biophys. Acta 1139 (1992) 169-183
39. Komarov P.G., Shtil A.A., Buckingham L.E., Balasubramanian M., Piraner O., Emanuele R.M., Roninson I.B., and Coon J.S. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int. J. Cancer 68 (1996) 245-250
40. Lo Y.L., and Huang J.D. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 59 (2000) 665-672
41. Ruetz S., and Gros P. Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. J. Biol. Chem. 270 (1995) 25388-25395
42. Batrakova E., Lee S., Li S., Venne A., Alakhov V., and Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16 (1999) 1373-1379
43. Miller D.W., Batrakova E.V., and Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. 16 (1999) 396-401
44. Zordan-Nudo T., Ling V., Liu Z., and Georges E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res. 53 (1993) 5994-6000
45. Batrakova E.V., Li S., Miller D.W., and Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16 (1999) 1366-1372
46. Regev R., Assaraf Y.G., and Eytan G.D. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur. J. Biochem. 259 (1999) 18-24
47. Sachs-Barrable K., Thamboo A., Lee S.D., and Wasan K.M. Lipid excipients Peceol® and Gelucire® 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 10 (2007) 350-362
48. Souza L.C., Maranhao R.C., Schreier S., and Campa A. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J. Antimicrob. Chemother. 32 (1993) 123-132
49. Reymond J.P., Sucker H., and Vonderscher J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 5 (1988) 677-679
50. Guerin P.J., Olliaro P., Sundar S., Boelaert M., Croft S.L., Desjeux P., Wasunna M.K., and Bryceson A.D. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2 8 (2002) 494-501
51. Sundar S., and Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15 6 (2002) 593-598